Identification of and Structural Insights into Hit Compounds Targeting N-Myristoyltransferase for Cryptosporidium Drug Development

Targeting RNA structures with small molecules

Identification of and Structural Insights into Hit Compounds Targeting N- Myristoyltransferase for Cryptosporidium Drug Development

IJMS, Free Full-Text

Rudimentary Structure-Activity-Relationship study of the MMV Pathogen Box compound MMV675968 (2,4-diaminoquinazoline) unveils novel inhibitors of Trypanosoma brucei brucei DHFR enzyme

Identification of and Structural Insights into Hit Compounds Targeting N- Myristoyltransferase for Cryptosporidium Drug Development

Computational approaches for drug discovery against trypanosomatid-caused diseases, Parasitology

Identification of and Structural Insights into Hit Compounds Targeting N- Myristoyltransferase for Cryptosporidium Drug Development

Targeting RNA structures with small molecules

Structure-Based Design of Potent and Selective Leishmania N- Myristoyltransferase Inhibitors

Michael FENWICK, Research Associate, Seattle Structural Genomics Center for Infectious Disease, Seattle, SSGCID

Identification of and Structural Insights into Hit Compounds Targeting N- Myristoyltransferase for Cryptosporidium Drug Development

Frontiers Cryptosporidium parvum Pyruvate Kinase Inhibitors With in vivo Anti-cryptosporidial Efficacy

Identification of and Structural Insights into Hit Compounds Targeting N- Myristoyltransferase for Cryptosporidium Drug Development

Targeting RNA structures with small molecules

Identification of and Structural Insights into Hit Compounds Targeting N- Myristoyltransferase for Cryptosporidium Drug Development